NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
57894-0501-01 | 57894-0501 | Amivantamab | Rybrevant | 350.0 mg/1 | Immunotherapy | Monoclonal Antibody | EGFR, MET | Intravenous | May 21, 2021 | In Use | |
73042-0201-01 | 73042-0201 | Naxitamab | DANYELZA | 40.0 mg/10mL | Immunotherapy | Monoclonal Antibody | GD2 | Intravenous | Nov 25, 2020 | In Use | |
00069-0315-01 | 00069-0315 | Bevacizumab-bvzr | Zirabev | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan 13, 2020 | In Use | |
42747-0761-01 | 42747-0761 | mogamulizumab-kpkc | POTELIGEO | 4.0 mg/mL | Immunotherapy | Monoclonal Antibody | CCR4 | Intravenous | Aug 8, 2018 | In Use | |
00069-4494-02 | 00069-4494 | Elranatamab-bcmm | Elrexfio | 76.0 mg/1.9mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug 15, 2023 | In Use | |
50242-0145-01 | 50242-0145 | Pertuzumab | Perjeta | 30.0 mg/mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 8, 2012 | In Use | |
55513-0164-01 | 55513-0164 | Traztuzumab-anns, trastuzumab-anns | Kanjinti | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Feb 1, 2023 | In Use | ||
78206-0148-01 | 78206-0148 | Ontruzant | Ontruzant | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 1, 2021 | In Use | ||
00069-2522-02 | 00069-2522 | Elranatamab-bcmm | Elrexfio | 44.0 mg/1.1mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Aug 15, 2023 | In Use | |
55513-0326-01 | 55513-0326 | rituximab-arrx | Riabni | 500.0 mg/50mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 6, 2021 | In Use | |
57894-0502-20 | 57894-0502 | Daratumumab | Darzalex | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Nov 16, 2015 | Nov 30, 2026 | In Use |
63459-0103-10 | 63459-0103 | Rituximab-abbs | Truxima | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | May 4, 2020 | In Use | |
55513-0206-01 | 55513-0206 | Bevacizumab-awwb | MVASI | 100.0 mg/4mL, 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 1, 2018 | In Use | |
50242-0260-01 | 50242-0260 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | Jun 29, 2020 | In Use | |
00173-0821-02 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jul 22, 2011 | Aug 31, 2017 | No Longer Used |
72606-0011-10 | 72606-0011 | Bevacizumab-adcd | Vegzelma | 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Apr 3, 2023 | In Use | |
75929-0787-36 | 75929-0787 | Tafasitamab-cxix | MONJUVI | 200.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD19 | Intravenous | Aug 5, 2020 | In Use | |
69448-0016-11 | 69448-0016 | Trastuzumab-strf | HERCESSI | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan 1, 2025 | In Use | |
55513-0141-01 | 55513-0141 | trastuzumab-anns | Kanjinti | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 28, 2019 | In Use | |
83257-0001-11 | 83257-0001 | Trastuzumab-dkst | OGIVRI | 150.0 mg/7.4mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 1, 2023 | In Use | |
57894-0421-01 | 57894-0421 | Siltuximab | Sylvant | 400.0 mg/1 | Immunotherapy | Monoclonal Antibody | Interleukin-6 Antagonists | Intravenous | Apr 1, 2014 | Jan 31, 2021 | No Longer Used |
00006-5034-02 | 00006-5034 | Ontruzant | Ontruzant | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Apr 15, 2020 | Sep 30, 2023 | No Longer Used | |
00310-4535-30 | 00310-4535 | Tremelimumab | IMJUDO | 300.0 mg/15mL | Immunotherapy | Monoclonal Antibody | CTLA-4 | Intravenous | Oct 21, 2022 | In Use | |
70710-1896-06 | 70710-1896 | Arsenic trioxide | Arsenic trioxide | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Feb 28, 2023 | In Use | |
49884-0724-01 | 49884-0724 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Feb 24, 1999 | In Use |
Found 11465 results — Export these results